FDA approves orphan drug vandetanib
7 April 2011 | By AstraZeneca
AstraZeneca today announced that the FDA approved the orphan drug vandetanib for the treatment of medullary thyroid cancer...
List view / Grid view
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
7 April 2011 | By AstraZeneca
AstraZeneca today announced that the FDA approved the orphan drug vandetanib for the treatment of medullary thyroid cancer...
28 March 2011 | By De Montfort University
De Montfort University’s unique QbD course received major endorsement by senior industry leaders when it was launched last week...
17 March 2011 | By GDS International
Personalised medicine is making a comeback – but will it stick this time?...
15 March 2011 | By AstraZeneca
AstraZeneca announced enrolment of the first patient in the Phase III clinical programme...
8 March 2011 | By AstraZeneca
The US FDA has accepted for review a New Drug Application (NDA) for dapagliflozin...
23 February 2011 | By AstraZeneca
The FDA has approved the inclusion of data from two clinical studies...
21 February 2011 | By AstraZeneca
AstraZeneca joins rivals looking to sidestep tougher rules on imported medicines as Russia drives to support domestic industry...
14 February 2011 | By GDS International
What are the strategies for reducing drug attrition rates in the clinic through the application of transgenic rodent models?...
7 February 2011 | By AstraZeneca
AstraZeneca today announced that the phase III ENTHUSE Study 15...
7 February 2011 | By AstraZeneca
This study is in addition to the companies’ Phase III RENAISSANCE programme for TC-5214...
4 February 2011 | By AstraZeneca
AstraZeneca announced today that the US FDA has acknowledged receipt of the company’s reply to the Complete Response Letter (CRL) for the ticagrelor New Drug Application (NDA)...
1 February 2011 | By AstraZeneca
The European Commission has granted marketing authorisation to FLUENZ Influenza Vaccine...
21 January 2011 | By AstraZeneca
AstraZeneca announced it has replied to the US FDA Complete Response Letter received for the ticagrelor (BRILINTA) New Drug Application...
3 January 2011 | By AstraZeneca
AstraZeneca has notified Abbott that it will discontinue the development of CERTRIAD on 22 January 2011...
2 December 2010 | By AstraZeneca
AstraZeneca announced the outcome of the US FDA Advisory Committee meeting...